GILD Investor Relations
Get all historical data on Gilead Sciences
Stop wasting time on manual entry and start making faster, smarter decisions with accurate, up-to-date GILD numbers you can trust.
- Deep dive into the latest Gilead Sciences earnings data, including segmental KPIs, GAAP to Non-GAAP, Guidance, Adjustments and more.
- Access the original source file in one click with hyperlink technology on every single data point.
- Use the data how you want it with our flexible delivery format.
Download now and get the data you need to stay ahead.
Get all the historical Gilead Sciences fundamental data in one place with the Daloopa Data Sheet.
Gilead Sciences SEC Filings & Financial Statements Last 5 Years
2024 Earnings
2023 Financial Disclosures
2023 - Q2
2023 - Q1
2022 Financial Disclosures
2022 - Q4
2022 - Q3
2022 - Q2
2022 - Q1
2021 Financial Disclosures
2021 - Q4
2021 - Q3
2021 - Q2
2021 - Q1
2020 Financial Disclosures
2020 - Q4
2020 - Q3
2020 - Q2
2020 - Q1
2019 Financial Disclosures
2019 - Q4
2019 - Q3
2019 - Q2
2019 - Q1
Gilead Sciences Investor Relations Presentation
Gilead Sciences, Inc. is a biopharmaceutical company dedicated to discovering, developing, and commercializing innovative therapeutics in areas of unmet medical need. The company’s primary focus includes treatments for HIV/AIDS, liver diseases such as hepatitis B and C, oncology, and inflammatory diseases. Gilead’s mission is to advance the care of patients suffering from life-threatening diseases worldwide.
Gilead Sciences Head of Investor Relations
The Head of Investor Relations at Gilead Sciences is Jacquie Ross, who has held this position since December 2020. She is responsible for managing investor communications and ensuring that stakeholders are informed about the company’s performance and strategic initiatives.
Gilead Sciences Investor Relations Email & Contact Us
For investor-related inquiries, Gilead Sciences can be contacted via email at investor_relations@gilead.com or by phone at (650) 574-3000. This contact information is essential for investors seeking updates or clarifications regarding their investments or the company’s performance.
GILD Last Stock Split
Gilead Sciences has executed several stock splits since its initial public offering. The most recent stock split occurred on January 28, 2013, when the company conducted a two-for-one split. Prior to this, there were multiple two-for-one splits in February 2001, March 2002, September 2004, and June 2007.
GILD Investor Relations Website
For detailed financial reports, press releases, and other investor-related information, visit Gilead Sciences’ Investor Relations website: https://investors.gilead.com/overview/default.aspx
Covering more companies?
Create a free account to access up to 5 free data sheets.
Daloopa is your gateway to the latest data during earnings, including KPIs, guidance, GAAP to Non-GAAP and more, all formatted for immediate use.
Are you ready to stop wasting time on manual entry and start making faster, smarter decisions with accurate, up-to-date numbers you can trust? Create your free account today and get the data you need to stay ahead.
Create Free Account
About Daloopa
We believe that AI technology can improve clarity and efficiency for investors and financial markets.
Daloopa was formed in 2019, inspired by our founders’ personal experience at Point72, a NYC- based/short equiy hedge. Accurate data is central to all investment decisions and can influence speed and confidence for decision-makers. We believe that institutional finance has an opportunity to embrace tech-driven accuracy and speed.
